n CLINICAL TRAIL HIGHLIGHTS
PCI was well tolerated and had no adverse effects on the quality of life. Headache was the most common side effect. The only grade 3 adverse event was headache, which occurred in 4% of patients. Late radiation effects were rare. Grade 3 late effects (severe headache or severe central nervous system dysfunction) developed in approximately 2% of patients.
Dr. Slotman concluded, “Patients with extensive disease- small cell lung cancer who respond to chemotherapy should now routinely be offered PCI.”
Final Results of the EORTC Intergroup Randomized Phase 3 Study 40983 Evaluating the Benefit of Perioperative FOLFOX4 Chemotherapy for Patients with Potentially Resectable Colorectal Cancer Liver Metastases
Perioperative chemotherapy provided benefit for patients with colorectal cancer who were treated with surgery for potentially resectable liver metastases. Bernard Nordlinger, MD, Ambroise Paré Hôpital, France, reported this finding on behalf of the European Organisation for Research and Treatment of Cancer.
Dr. Nordlinger noted that liver metastases recur in approximately two-thirds of patients who are treated with surgery alone. He explained that the addition of perioperative chemotherapy would help to reduce the size of liver metastases before surgery. The addition of postoperative chemotherapy would help to kill dormant cancer cells in the remaining portion of the liver. The chemotherapy regimen (6 cycles of FOLFOX4) was chosen because of its response rates of more than 50% among patients with metastatic colorectal cancer.
The study included 364 patients with potentially resectable liver metastases demonstrated on computerized tomography (CT). The patients were randomly assigned to the perioperative chemotherapy and surgery arm (182 patients) or to the surgery alone arm (182 patients). Resection of the liver was actually done in 151 patients in the perioperative chemotherapy arm and in 152 patients in the surgery alone arm. The primary endpoint of the study was progression-free survival (PFS).
Perioperative chemotherapy led to a 29.5% decrease in the size of the liver lesion (from a median of 45 mm to 30 mm). A complete response was achieved in 3.8% of
patients and a partial response in 40.1% of patients after perioperative chemotherapy. Disease remained stable in 35.2% of patients. Disease progressed in 6.6%.
At interim analysis, the Independent Data Monitoring Committee authorized an early release of the final data. Perioperative chemotherapy was associated with better PFS for the total patient population (Table 1). Subgroup analysis demonstrated that better PFS was associated with perioperative chemotherapy for the eligible patient population, or the 171 patients in each arm who had evidence of resectable metastases on CT (Figure 1A). The PFS rate also favored perioperative chemotherapy among the patients who had liver resection (Figure 1B).
Table 1. Results.
n pts CT
All patients
All eligible patients
All resected patients
182 171 151 n pts
Surgery 182
171 152
% absolute difference in 3-year PFS
+7.2%
(28.1% to 35.4%) +8.1%
(28.1% to 36.2%) +9.2%
(33.2% to 42.4%)
Hazard Ratio
(Confidence Interval)
0.79
(0.62-1.02) 0.77
(0.60-1.00) 0.73
(0.55-0.97)
Figure 1A. PFS in Eligible Patients. HR= 0.77; CI: 0.60-1.00, p=0.041
100
10 20 30 40 0 60 70 80 0
0 0
12 171 11 171
1 83 11 2 74 3
er o patiets at ris 7
:
37 43
22 21
8
Figure 1B. PFS in Resected Patients. HR= 0.73; CI: 0.55-0.97, p=0.025 +9.2%
00
0 20 30 40 50 0 70 0 90
0 0
04 52 93 5
5
2 7 3
uer o patients at ris 59
:
39 45
24 23
0
4 5 Periop CT 42.4% Surgery only 33.2% years At 3 years 4 6 +8.1% Periop CT 36.2% rery oy 28.1% years At 3 years p value p=0.058 p=0.041 p=0.025
12
August 2007
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30